Quick Answer
Adaptimmune Therapeutics PLC reported R&D Expense of $149.06 million for fiscal year 2024.
Adaptimmune Therapeutics PLC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $149.06M | +17.8% |
| 2023 | $126.51M | -1.0% |
| 2022 | $127.73M | +15.0% |
| 2021 | $111.09M | +21.3% |
| 2020 | $91.57M | -6.1% |
| 2019 | $97.50M | -0.8% |
| 2018 | $98.27M | +12.5% |
| 2017 | $87.39M | +37.0% |
| 2016 | $63.79M | +164.3% |
| 2015 | $24.14M | +152.1% |
| 2014 | $9.57M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $22.98M | -43.2% | -20.4% |
| March 31, 2025 | $28.86M | -18.0% | -15.9% |
| September 30, 2024 | $34.30M | -9.2% | -15.2% |
| June 30, 2024 | $40.45M | +35.0% | +14.9% |
| March 31, 2024 | $35.21M | +37.8% | -6.8% |
| September 30, 2023 | $37.79M | +13.9% | +26.1% |
| June 30, 2023 | $29.96M | -13.7% | +17.3% |
| March 31, 2023 | $25.55M | -30.5% | -23.0% |
- Adaptimmune Therapeutics PLC showed an increase of +17.8% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2024 period, Adaptimmune Therapeutics PLC’s r&d expense has grown by 1456.8% (from $9.57 million to $149.06 million).
- The most recent figure is from Adaptimmune Therapeutics PLC’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: